Recherche Recherche de structure
wx_img
Inquiry Form
  1. Home
  2. Zuranolone

Zuranolone

ZURZUVAE was approved by the FDA in August 2023 as the first-and-only oral treatment specifically indicated for adults with postpartum depression (PPD). Zuranolone is a next-generation positive allosteric modulator (PAM) of GABAA receptors being evaluated as a treatment for various affective disorders.

(5R,8R,9R,10S,13S,14S)-13-Methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
(5R,8R,9R,10S,13S,14S)-13-Methyltetradecahydro-3H-cyclopenta[a]phenanthrene-3,17(2H)-dione
CM360817
5696-51-5
(3α,5β)-3-Hydroxy-3-methylestran-17-one
(3α,5β)-3-Hydroxy-3-methylestran-17-one
CM1045894
1632051-92-3
(3α,5β)-3-Methyl-19-norpregn-17(20)-en-3-ol
(3α,5β)-3-Methyl-19-norpregn-17(20)-en-3-ol
CM1045895
1430063-91-4
(3α,5β)-3-Methyl-19-norpregnane-3,20-diol
(3α,5β)-3-Methyl-19-norpregnane-3,20-diol
CM1045896
1430063-92-5
1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone
1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-diMethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone
CM761423
162882-77-1
2-Bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone
2-Bromo-1-((3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone
CM360849
1430063-93-6